Phibro Animal Health Co. (NASDAQ:PAHC) Given Average Rating of “Strong Sell” by Brokerages

Phibro Animal Health Co. (NASDAQ:PAHC) has been given an average rating of “Strong Sell” by the five ratings firms that are presently covering the company, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating and two have given a hold rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $15.00.

Several research firms have issued reports on PAHC. Bank of America lifted their price target on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research note on Friday, August 30th. JPMorgan Chase & Co. started coverage on shares of Phibro Animal Health in a research note on Tuesday, September 10th. They set a “neutral” rating and a $22.00 price target for the company.

Insider Activity

In related news, Director E Thomas Corcoran bought 5,000 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was bought at an average price of $20.02 per share, for a total transaction of $100,100.00. Following the purchase, the director now owns 25,000 shares in the company, valued at approximately $500,500. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 50.06% of the company’s stock.

Institutional Investors Weigh In On Phibro Animal Health

Several hedge funds have recently bought and sold shares of the stock. Jacobs Levy Equity Management Inc. lifted its holdings in Phibro Animal Health by 56.0% during the 1st quarter. Jacobs Levy Equity Management Inc. now owns 79,667 shares of the company’s stock worth $1,030,000 after purchasing an additional 28,584 shares during the last quarter. Illinois Municipal Retirement Fund increased its position in Phibro Animal Health by 7.2% during the 1st quarter. Illinois Municipal Retirement Fund now owns 11,430 shares of the company’s stock worth $148,000 after buying an additional 765 shares during the period. Acadian Asset Management LLC lifted its holdings in shares of Phibro Animal Health by 32.8% during the first quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock worth $8,726,000 after buying an additional 166,776 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Phibro Animal Health by 290.2% in the fourth quarter. BNP Paribas Financial Markets now owns 73,287 shares of the company’s stock valued at $849,000 after acquiring an additional 54,506 shares during the period. Finally, Price T Rowe Associates Inc. MD grew its stake in shares of Phibro Animal Health by 7.4% in the first quarter. Price T Rowe Associates Inc. MD now owns 15,393 shares of the company’s stock valued at $200,000 after acquiring an additional 1,063 shares in the last quarter. 99.34% of the stock is currently owned by institutional investors and hedge funds.

Phibro Animal Health Trading Down 2.1 %

Shares of NASDAQ:PAHC opened at $21.53 on Tuesday. The firm has a market cap of $872.03 million, a price-to-earnings ratio of 67.28, a PEG ratio of 1.70 and a beta of 0.52. The company has a quick ratio of 1.64, a current ratio of 2.94 and a debt-to-equity ratio of 1.79. Phibro Animal Health has a 12 month low of $9.40 and a 12 month high of $22.31. The company’s fifty day simple moving average is $18.99 and its 200 day simple moving average is $16.68.

Phibro Animal Health Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Shareholders of record on Wednesday, September 4th will be given a dividend of $0.12 per share. The ex-dividend date is Wednesday, September 4th. This represents a $0.48 dividend on an annualized basis and a yield of 2.23%. Phibro Animal Health’s dividend payout ratio (DPR) is 150.00%.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.